February 6, 2017
Kiadis Pharma in phase 3 with leukemia drug ATIR101
Kiadis Pharma has started its phase III trial with its major products for blood cancer hematopoietic stem cell transplantation (HSCT) ATIR101.
pharmaceutical daily
Pharmaceuticals, Biotechnology and Life Sciences
February 6, 2017
Innate Pharma’s acute myeloid leukemia drug testing disappoints
Innate Pharma’s “EffiKIR” trial of lirilumab as a single agent maintenance treatment in elderly patients with acute myeloid leukemia (AML) in first complete remission, did not meet its primary efficacy endpoint of leukemia-free survival (LFS).
February 6, 2017
Ablynx submits its thrombosis antibody to EMA
Ablynx has applied its caplacizumab to European Medicines Agency for approval to use it for a form of blod clotting disorder.
February 6, 2017
TiGenix to present results of Crohn`s disease drug trial at ECCO
TiGenix will present results from its Phase III trial of Crohn`s disease drug, named Cx601, at the upcoming 12th Annual Congress of the…
February 6, 2017
Portola nets $150M deal with HealthCare Royalty Partners
Portola Pharmaceuticals has signed a $150 million royalty deal with HealthCare Royalty Partners (HCR).
February 4, 2017
World Cancer Day: Worldwide cases of cancer predicted to reach 21.7 million by 2030
Coordinated by Union for International Cancer Control (UICC), World Cancer Day is this year taking place under the tagline ‘We can. I can.’ and explores how everyone – as a collective or as individuals – can do their part to reduce the global burden of cancer.
February 3, 2017
Sobi negotiates sale of its Partner Products business area
Swedish Orphan Biovitrum is negotiating with a private equity firm regarding a possible sale of its Partner Products business area excluding Kineret and Orfadin.
February 3, 2017
Allergan expects annual dividend rise
Allergan’s boss Brent Saunders said that the company plans to increase dividend on an annual basis over time.
February 3, 2017
ESC: Air pollution impairs the function of blood vessels in the lungs
Dr Jean-Francois Argacha, a cardiologist at the University Hospital (UZ) Brussels, Belgium, said that this is the first study that reports an influence of air pollution on pulmonary vascular function and it represents major public health issue for people living in polluted urban areas where exercise could damage the lungs and potentially lead to decompensated heart failure.
February 3, 2017
DBV Technologies completes P II study of milk-induced EoE treatment
DBV Technologies has completed a Phase IIA investigator-initiated clinical trial of Viaskin Milk for the treatment of milk-induced Eosinophilic Esophagitis (EoE) in children ages 4-17 has been completed.